Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.45
Bid: 6.30
Ask: 6.60
Change: -0.25 (-3.73%)
Spread: 0.30 (4.76%)
Open: 6.70
High: 6.70
Low: 6.15
Yest. Close: 6.70
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Nuformix PLC - AGM Results

Tue, 10th Sep 2019 16:49

RNS Number : 8767L
Nuformix PLC
10 September 2019
 

10th September 2019

 

Nuformix plc

("Nuformix" or "the Group"),

 

Result of Annual General Meeting

 

The Annual General Meeting of Nuformix plc was held on 10 September 2019 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0HR.

 

As announced this morning resolution 7 was withdrawn from the meeting. The Directors of the Company wish to announce that all other resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.  The results of the proxy voting position received in advance of the meeting are reported below:

 


Resolution

Ordinary/ Special

For


Against


Total votes cast




No. of votes

%

No. of votes

%


1

To receive the annual report and accounts for the year ended 31 March 2019

 

Ordinary

121,471,999

100

0

0

121,471,999

2

To approve the Annual Report on Remuneration

 

Ordinary

121,413,979

 

100

0

0

121,413,979

 

3

To re-appoint David Tapolczay as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

4

To re-appoint Daniel Gooding as a director

 

Ordinary

121,471,999

 

100

0

0

121,471,999

 

5

To re-appoint Joanne Holland as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

6

To re-appoint John Lidgey as a director

 

Ordinary

83,841,906

 

99.85

123,641

 

0.15

83,965,547

 

7

To re-appoint Kirk Siderman-Wolter as a director

 

Ordinary

Withdrawn





8

To re-Christopher Blackwell as a director

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

9

To re-appoint haysmacintyre as auditor

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

10

To authorise the Directors to determine the auditor's fees.

 

Ordinary

121,465,547

 

100

0

0

121,465,547

 

11

To authorise the Directors to allot shares.

 

Ordinary

121,471,999

 

100

0

0

121,471,999

 

12

To authorise the Directors to disapply pre-emption rights.

 

Special

121,465,547

 

100

0

0

121,465,547

 

13

To authorise the Company to purchase its own shares.

 

Special

121,471,999

 

100

0

0

121,471,999

 

14

To authorise calling of a general meeting on 14 clear days' notice.

 

Special

121,471,999

 

100

0

0

121,471,999

 

 

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

The Company's issued share capital is 469,466,512 ordinary shares of £0.001 each. Copies of the resolutions passed as special resolutions at the AGM will shortly be available for inspection at the National Storage Mechanism, which is located at: http://www.morningstar.co.uk/uk/nsm.

 

Enquiries:

Nuformix plc

Dr Dan Gooding, Chief Executive Officer

+44 (0)1223 423667

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Email: nuformix@optimumcomms.com

+44 (0) 203 950 9144

 

 

About Nuformix plc: www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGLLFSEADIILIA
Date   Source Headline
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension

Login to your account

Don't have an account? Click here to register.